4.1 billion US dollars! Thermo Fisher Scientific acquires Solventum’s purification and filtration business

June 5, 2025  Source: drugdu 63

 

On February 25th, Thermo Fisher Scientific (NYSE: TMO) announced that it has reached a final agreement with Solventum (NYSE: SOLV) to acquire Solventum's purification and filtration business for approximately $4.1 billion in cash. The transaction is expected to be completed by the end of 2025.

Affected by this transaction, the stock price of Thermo Fisher Scientific rose by 4%, and the stock price of Solventum rose by 10%. The transaction is expected to remain neutral on Solventum's 2025 earnings per share (EPS) and is expected to bring in approximately $3.4 billion in net income, with Solventum's plan primarily focused on reducing debt.

This acquisition is expected to bring mid to high single digit organic growth to Thermo Fisher Scientific. By applying the PPI business system, the company will achieve strong profit expansion and significant synergies. In the first year after the completion of the transaction, it is expected that adjusted earnings per share (EPS) will decrease by $0.06, but excluding financing costs, it is expected to increase by $0.28. By the fifth year after the completion of the transaction, Thermo Fisher expects to achieve approximately $125 million in adjusted operating revenue through revenue and cost synergies. In the long run, the internal rate of return for this transaction is expected to exceed double digits.

In addition, Solventum's purification and filtration business is highly complementary to Thermo Fisher Scientific's bioproduction business. Nowadays, Thermo Fisher Scientific has a leading product portfolio in cell culture media and disposable technology. Solventum's innovative filtration product portfolio expands Thermo Fisher Scientific's capabilities in biopharmaceutical development and manufacturing, covering both upstream and downstream workflows.

According to the official website, Solventum's purification business generated approximately $1 billion in revenue in 2024, providing filters for purifying biologics and other medical technologies. The company stated that this acquisition will expand Thermo Fisher Scientific's biological processing capabilities and production of biologics.

Source: https://news.yaozh.com/archive/45050.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.